A new drug has shown promise in combating Parkinson’s disease while minimizing unwanted side effects. The once-daily pill, tavapadon, was found to relieve symptoms — including stiffness, coordination, ...
When the hospital germ Pseudomonas aeruginosa infects the body, it uses the sugar-binding protein LecA to attach itself to ...
Scott Rider of South Carolina is one of over 1 million people in the United States with Parkinson's disease. Working closely ...
The age-old advice to "trust your gut" could soon take on new meaning for people diagnosed with Parkinson's disease, thanks ...
Symptoms of Parkinson’s disease, such as tremors and stiffness, can make daily tasks difficult. A new drug has shown promise in alleviating symptoms. Tavapadon, a drug being tested to treat early ...
Merck KGaA has teamed up with Flagship Pioneering's Valo Health on an ambitious project to apply AI to the discovery of novel ...
Submission supported by data from the Phase 3 TEMPO program that demonstrated symptomatic improvement across the Parkinson's disease spectrum Positive results across all three Phase 3 TEMPO trials ...
Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering ...
Pharmaceutical Technology on MSN
Merck KGaA eyes new Parkinson’s disease assets with $3bn Valo partnership
Valo will use its trove of patient records and biobank samples to pinpoint potential targets for Merck’s pipeline expansion.
New research has revealed that Parkinson's disease causes significant and progressive changes to blood vessels in the brain, ...
A new drug has shown promise in combating Parkinson’s disease while minimizing unwanted side effects. The once-daily pill, tavapadon, was found to relieve symptoms — including stiffness, coordination, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback